Rhenium-186 Nanoliposome
Phase 1Small molecule
Rhenium-186 Nanoliposome is one of 25 small molecule programs targeting Ependymoma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
34 competitors in Ependymoma
#DrugCompanyPhaseTrials
1Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Bicnu
MMelissa K Accordino
Approved
Adrucil
EElorac, Inc.
Approved
Oncovin
Eli LillyPhase 3
Paraplatin
AAvyxa
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Mesnex
BBaxter Healthcare Corporation
Phase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Tykerb
GSKPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rhenium-186 Nanoliposome. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- PPlus Therapeutics